Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Bach

Showing results (41-50 of 202) with videos related to

Pageof 21
Sort By:
JAMA|May 1, 2018
Value-Based Pricing for Drugs: Theme and VariationsAnna Kaltenboeck, Peter B Bach
JAMA|October 26, 2018
Defining Value-Based Pricing of Drugs-ReplyAnna Kaltenboeck, Peter B Bach
Critical Care Clinics|July 27, 2002
The epidemiology and costs of chronic critical illnessShannon S Carson, Peter B Bach
JAMA|March 18, 2010
Cancer's next frontier: addressing high and increasing costsElena B Elkin, Peter B Bach
Journal of the National Cancer Institute|October 24, 2017
Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung CancerPeter B Bach, Leonard B Saltz
The New England Journal of Medicine|June 2, 2006
The first months of the prescription-drug benefit--a CMS updatePeter B Bach, Mark B McClellan
JAMA|April 24, 2013
Cost consequences of the 340B drug discount programRena M Conti, Peter B Bach
JAMA Internal Medicine|May 29, 2013
Overuse of health care services: when less is more … more or lessAllison Lipitz-Snyderman, Peter B Bach
Journal of the National Cancer Institute|June 6, 2002
Re: All-cause mortality in randomized trials of cancer screeningColin B Begg, Peter B Bach
The New England Journal of Medicine|January 31, 2014
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancerLeonard B Saltz, Peter B Bach
Pageof 21

Showing results (41-50 of 202) with videos related to

Sort By:
Pageof 21
JAMA|May 1, 2018
Value-Based Pricing for Drugs: Theme and VariationsAnna Kaltenboeck, Peter B Bach
JAMA|October 26, 2018
Defining Value-Based Pricing of Drugs-ReplyAnna Kaltenboeck, Peter B Bach
Critical Care Clinics|July 27, 2002
The epidemiology and costs of chronic critical illnessShannon S Carson, Peter B Bach
JAMA|March 18, 2010
Cancer's next frontier: addressing high and increasing costsElena B Elkin, Peter B Bach
Journal of the National Cancer Institute|October 24, 2017
Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung CancerPeter B Bach, Leonard B Saltz
The New England Journal of Medicine|June 2, 2006
The first months of the prescription-drug benefit--a CMS updatePeter B Bach, Mark B McClellan
JAMA|April 24, 2013
Cost consequences of the 340B drug discount programRena M Conti, Peter B Bach
JAMA Internal Medicine|May 29, 2013
Overuse of health care services: when less is more … more or lessAllison Lipitz-Snyderman, Peter B Bach
Journal of the National Cancer Institute|June 6, 2002
Re: All-cause mortality in randomized trials of cancer screeningColin B Begg, Peter B Bach
The New England Journal of Medicine|January 31, 2014
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancerLeonard B Saltz, Peter B Bach
Pageof 21